1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

Jean Yves Blay; Sylvie Chevret; Nicolas Penel; François Bertucci; Emmanuelle Bompas; Esma Saâda-Bouzid; J-C. Eymard; JP Lotz; Elodie Coquan; Roland Schött; P Soulié; Claude Linassier; Axel Le Cesne; Mehdi Brahmi; Natalie Hoog-Labouret; Frédéric Legrand; Clotilde Simon; Assia Lamrani-Ghaouti; Isabelle Laure Ray-Coquard; Christophe Massard

doi:10.1016/j.annonc.2020.08.1845

Related publications

Article2021

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

Jean Yves Blay, Nicolas Penel, Isabelle Laure Ray-Coquard, Sophie Cousin, François Bertucci, Emmanuelle Bompas, Jean‐Christophe Eymard, Esma Saâda-Bouzid, P Soulié, Pascaline Boudou‐Rouquette, Armelle Dufresne, Axel Le Cesne, Olivier Mir, Laëtitia Gambotti, Frédéric Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Sylvie Chevret, Christophe Massard

Article2023

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Jean Yves Blay, Sylvie Chevret, Axel Le Cesne, Mehdi Brahmi, Nicolas Penel, Sophie Cousin, François Bertucci, Emmanuelle Bompas, Thomas Ryckewaert, Pauline Soibinet, Pascaline Boudou‐Rouquette, Esma Saada Bouzid, P Soulié, Thibaud Valentin, Jean‐Pierre Lotz, Diégo Tosi, Zoé Nevière, Mathilde Cancel, Isabelle Ray‐Coquard, Laëtitia Gambotti, Frédéric Legrand, ,

Article2020

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN

Marie Morfouace, Aleksandra Stevovic, Marie Vinches, Vassilis Golfinopoulos, Dexter X. Jin, Oliver Holmes, Rachel Erlich, Jérôme Fayette, Sabrina Croce, Isabelle Ray‐Coquard, Nicolas Girard, Jean Yves Blay

Article2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, ,

Article2012

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders

Flora Peyvandi, Roberta Palla, Marzia Menegatti, Simona Maria Siboni, Susan Halimeh, Britta Faeser, Helen Pergantou, Helen Platokouki, Paul Giangrande, Kathelijne Peerlinck, Tıraje Celkan, Nihal Özdemir, Christoph Bidlingmaier, J. Ingerslev, Muriel Giansily‐Blaizot, Jean‐François Schved, Ruth Gilmore, Alain Gadisseur, Majda Benedik‐Dolničar, Lidija Kitanovski, Danijela Miković, Khaled M. Musallam,